Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 150.97
ATHX's Cash to Debt is ranked higher than
54% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. ATHX: 150.97 )
Ranked among companies with meaningful Cash to Debt only.
ATHX' s Cash to Debt Range Over the Past 10 Years
Min: 0.12  Med: 9999.00 Max: No Debt
Current: 150.97
Equity to Asset 0.51
ATHX's Equity to Asset is ranked lower than
68% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ATHX: 0.51 )
Ranked among companies with meaningful Equity to Asset only.
ATHX' s Equity to Asset Range Over the Past 10 Years
Min: 0.19  Med: 0.64 Max: 0.93
Current: 0.51
0.19
0.93
Interest Coverage No Debt
ATHX's Interest Coverage is ranked higher than
73% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ATHX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ATHX' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: -12.44
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1755.13
ATHX's Operating margin (%) is ranked lower than
82% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. ATHX: -1755.13 )
Ranked among companies with meaningful Operating margin (%) only.
ATHX' s Operating margin (%) Range Over the Past 10 Years
Min: -1787.55  Med: -501.69 Max: -128.77
Current: -1755.13
-1787.55
-128.77
Net-margin (%) -1683.65
ATHX's Net-margin (%) is ranked lower than
82% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. ATHX: -1683.65 )
Ranked among companies with meaningful Net-margin (%) only.
ATHX' s Net-margin (%) Range Over the Past 10 Years
Min: -1360.57  Med: -492.72 Max: -127.27
Current: -1683.65
-1360.57
-127.27
ROE (%) -138.55
ATHX's ROE (%) is ranked lower than
87% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. ATHX: -138.55 )
Ranked among companies with meaningful ROE (%) only.
ATHX' s ROE (%) Range Over the Past 10 Years
Min: -1685200  Med: -118.99 Max: -45.44
Current: -138.55
-1685200
-45.44
ROA (%) -77.79
ATHX's ROA (%) is ranked lower than
81% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. ATHX: -77.79 )
Ranked among companies with meaningful ROA (%) only.
ATHX' s ROA (%) Range Over the Past 10 Years
Min: -1459900  Med: -69.13 Max: -41.79
Current: -77.79
-1459900
-41.79
ROC (Joel Greenblatt) (%) -2219.94
ATHX's ROC (Joel Greenblatt) (%) is ranked lower than
71% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. ATHX: -2219.94 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ATHX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1397000  Med: -2121.98 Max: -1237.26
Current: -2219.94
-1397000
-1237.26
Revenue Growth (3Y)(%) -64.60
ATHX's Revenue Growth (3Y)(%) is ranked lower than
88% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. ATHX: -64.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ATHX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -56.00 Max: 41.2
Current: -64.6
0
41.2
EBITDA Growth (3Y)(%) -14.70
ATHX's EBITDA Growth (3Y)(%) is ranked lower than
64% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. ATHX: -14.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ATHX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -32.30 Max: -10.7
Current: -14.7
EPS Growth (3Y)(%) -19.00
ATHX's EPS Growth (3Y)(%) is ranked lower than
68% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. ATHX: -19.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ATHX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -31.60 Max: -3.9
Current: -19
» ATHX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

ATHX Guru Trades in Q4 2014

First Eagle Investment 712,500 sh (-40.52%)
» More
Q1 2015

ATHX Guru Trades in Q1 2015

Ronald Muhlenkamp 10,150 sh (New)
First Eagle Investment 807,601 sh (+13.35%)
First Eagle Investment 2,500 sh (unchged)
» More
Q2 2015

ATHX Guru Trades in Q2 2015

First Eagle Investment Sold Out
Ronald Muhlenkamp Sold Out
» More
Q4 2015

ATHX Guru Trades in Q4 2015

Jim Simons 112,834 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with ATHX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 17.36
ATHX's Forward P/E is ranked lower than
52% of the 341 Companies
in the Global Biotechnology industry.

( Industry Median: 16.50 vs. ATHX: 17.36 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 6.51
ATHX's P/B is ranked lower than
92% of the 1128 Companies
in the Global Biotechnology industry.

( Industry Median: 2.89 vs. ATHX: 6.51 )
Ranked among companies with meaningful P/B only.
ATHX' s P/B Range Over the Past 10 Years
Min: 0.18  Med: 4.27 Max: 25.33
Current: 6.51
0.18
25.33
P/S 64.12
ATHX's P/S is ranked lower than
89% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 8.77 vs. ATHX: 64.12 )
Ranked among companies with meaningful P/S only.
ATHX' s P/S Range Over the Past 10 Years
Min: 1.16  Med: 9.30 Max: 320
Current: 64.12
1.16
320
Current Ratio 2.05
ATHX's Current Ratio is ranked lower than
74% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. ATHX: 2.05 )
Ranked among companies with meaningful Current Ratio only.
ATHX' s Current Ratio Range Over the Past 10 Years
Min: 0.47  Med: 4.44 Max: 12.58
Current: 2.05
0.47
12.58
Quick Ratio 2.05
ATHX's Quick Ratio is ranked lower than
70% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. ATHX: 2.05 )
Ranked among companies with meaningful Quick Ratio only.
ATHX' s Quick Ratio Range Over the Past 10 Years
Min: 0.47  Med: 4.44 Max: 12.58
Current: 2.05
0.47
12.58
Days Sales Outstanding 72.86
ATHX's Days Sales Outstanding is ranked lower than
55% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. ATHX: 72.86 )
Ranked among companies with meaningful Days Sales Outstanding only.
ATHX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 20.54  Med: 77.85 Max: 156.08
Current: 72.86
20.54
156.08

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.75
ATHX's Price/Net Cash is ranked lower than
54% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: 5.54 vs. ATHX: 7.75 )
Ranked among companies with meaningful Price/Net Cash only.
ATHX' s Price/Net Cash Range Over the Past 10 Years
Min: 0.33  Med: 6.02 Max: 23
Current: 7.75
0.33
23
Price/Net Current Asset Value 7.29
ATHX's Price/Net Current Asset Value is ranked lower than
51% of the 893 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ATHX: 7.29 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ATHX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.32  Med: 5.78 Max: 69.5
Current: 7.29
0.32
69.5
Price/Tangible Book 6.53
ATHX's Price/Tangible Book is ranked lower than
58% of the 1047 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. ATHX: 6.53 )
Ranked among companies with meaningful Price/Tangible Book only.
ATHX' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.27  Med: 4.33 Max: 23.17
Current: 6.53
0.27
23.17
Price/Median PS Value 13.78
ATHX's Price/Median PS Value is ranked lower than
96% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 1.24 vs. ATHX: 13.78 )
Ranked among companies with meaningful Price/Median PS Value only.
ATHX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.16  Med: 1.00 Max: 32
Current: 13.78
0.16
32
Earnings Yield (Greenblatt) (%) -36.86
ATHX's Earnings Yield (Greenblatt) (%) is ranked lower than
82% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. ATHX: -36.86 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ATHX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -40.77  Med: 206.20 Max: 17247.5
Current: -36.86
-40.77
17247.5

More Statistics

Revenue(Mil) $2
EPS $ -0.37
Beta-1.19
Short Percentage of Float3.20%
52-Week Range $0.90 - 3.43
Shares Outstanding(Mil)83.29

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 5 10 2 3
EPS($) -0.27 -0.28 -0.32 -0.24
EPS without NRI($) -0.27 -0.28 -0.32 -0.24

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:4LS.Germany,
Athersys Inc was incorporated in Delaware on October 24, 1995. On June 8, 2007, it merged with a wholly owned subsidiary of BTHC VI, Inc., a Delaware corporation, and, on August 31, 2007, BTHC VI, Inc. changed its name to Athersys, Inc. It is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates. The Companys current product development portfolio consists of MultiStem, a patented and proprietary stem cell product that it is developing as a treatment for multiple disease indications, and that is currently being evaluated in two ongoing clinical trials. In addition, it is developing pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, narcolepsy or other forms of excessive daytime sleepiness. Its business objective is to discover, develop and commercialize novel therapeutic products for disease indications that represent areas of clinical need and commercial opportunity. Its partner, Pfizer Inc. is conducting Phase 2 clinical study of MultiStem cells. Myocardial infarction is one of the causes of death and disability in the United States. The Company is engaged in five programs including, Inflammatory Bowel Disease; Ischemic Stroke; Acute Myocardial Infarction; Hematopoietic Stem Cell Transplant / GvHD; Multistem. The Company partners with Pfizer, RTI, Angiotech and Bristol-Myers Squibb. It competes with Stem Cells Inc., Johnson & Johnson, Celgene Corporation, or Celgene, Advanced Cell Technology, Inc. The Company has 36 issued patents; 16 United States and 20 international. The Company and its related programs and the products are subject to government regulations.
» More Articles for ATHX

Headlines

Articles On GuruFocus.com
Athersys Inc. (ATHX) CEO Bokkelen Gil Van buys 10,000 Shares Mar 18 2009 

More From Other Websites
Rodman & Renshaw's Ram Selvaraju Interviewed by The Life Sciences Report Feb 11 2016
Athersys’ MultiStem® Data to be Presented at International Stroke Conference 2016 Feb 10 2016
Athersys to Host Year End 2015 Financial Results Call Feb 09 2016
Athersys to Present at 18th Annual BIO CEO & Investor Conference Feb 01 2016
Athersys to Present at 18th Annual BIO CEO & Investor Conference Feb 01 2016
Athersys and Healios Announce R&D Day Jan 26 2016
Athersys and Healios Announce R&D Day Jan 26 2016
ATHERSYS, INC / NEW Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in... Jan 13 2016
Publication Provides Further Confirmation of the Potential for Athersys' MultiStem® Cell Therapy to... Jan 13 2016
Publication Provides Further Confirmation of the Potential for Athersys’ MultiStem® Cell Therapy... Jan 13 2016
Athersys, Inc. (NASDAQ: ATHX) to Receive License Fee of $15 million Jan 11 2016
Athersys (ATHX) Stock Advances on Healios Licensing Agreement Jan 08 2016
Athersys Soars on Japanese License Deal Jan 08 2016
Here’s Why Investors Are Piling Into These Five Stocks Jan 08 2016
Healios and Athersys Enter Into Regenerative Medicine Partnership for Treatment of Stroke Using... Jan 08 2016
Healios and Athersys Enter Into Regenerative Medicine Partnership for Treatment of Stroke Using... Jan 08 2016
Healios and Athersys Enter Into Regenerative Medicine Partnership for Treatment of Stroke Using... Jan 08 2016
Athersys to Present at Biotech Showcase(TM) 2016 Jan 04 2016
Athersys to Present at Biotech Showcase(TM) 2016 Jan 04 2016
Athersys, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 21 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK